Skip to main content

GSK Plc

Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
Values in USD · ADR · Reports in GBP

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

Did you know?

Trading 32% above its estimated fair value of $34.50.

Current Price

$50.90

-1.38%

GoodMoat Value

$34.50

32.2% overvalued
Profile
Valuation (TTM)
Market Cap$103.72B
P/E13.09
EV
P/B4.57
Shares Out2.04B
P/Sales2.34
Revenue$44.31B
EV/EBITDA12.73

GSK Plc (GSK) Valuation

GSK Fair Value Estimate

$34.5032.2% overvalued

Blended fair value estimate based on DCF, Graham Number, and earnings-based models.

GSK Valuation Metrics

FCF$8.67B
FCF Growth Rate-0.64%
EPS Growth (CAGR)3.98%
WACC10.00%

GSK Valuation & Fair Value Analysis

GSK Plc (GSK) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.

The GoodMoat Fair Value target for GSK Plc is $34.50. The current stock price is $50.90, suggesting the stock is 47.5% overvalued.

The price-to-earnings (P/E) ratio is 13.09. Price-to-book ratio is 4.57. Price-to-sales ratio is 2.34. Enterprise value to EBITDA is 12.73. PEG ratio is 1.48.

GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of GSK Plc's intrinsic value.